“The best outcomes, explains Dr. Modak, “occur when the medication is administered within 3 to 4.5 hours of the onset of ...

HealthDay News — More than one in four critically ill patients with stroke experience delirium, according to a study published online July 1 in the American Journal of Critical Care.

Transient ischemic attacks (TIAs), commonly known as "mini-strokes," are often brushed off despite being serious warning signs of a potential stroke. A 2017 American Heart Association study revealed ...

Scientists have discovered novel drug candidates which could ultimately lead to new effective treatments for conditions ...

The session focused on the evolution of stroke care, particularly ischemic strokes, which make up 87% of all strokes. It ...

Older Black patients on Medicare in the United States experience disparities in stroke care access and outcomes, compared with White patients.

The device, called a milli-spinner, is a tiny, powerfully rotating hollow tube outfitted with fins and slits. In action, both ...

Here we report that tissue plasminogen activator (tPA), known as a clot buster for clinical treatment of ischemic stroke, exerts additional neurorestorative effects in a murine model of stroke by ...

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

– TNKase® (tenecteplase) is the first stroke medicine approved by the FDA in nearly 30 years – – Single five-second intravenous bolus provides faster and simpler administration than the approved ...

DiaMedica's DM199 shows promise for Acute Ischemic Stroke, but caution is advised due to low market cap and trial outcome uncertainties. See more on DMAC here.

THURSDAY, Oct. 17, 2024 (HealthDay News) -- For patients with acute ischemic stroke (AIS), tenecteplase (TNK) has improved functional outcome and reduced disability and similar safety to alteplase ...